فهرست مطالب mona sadat larijani

The COVID-19 pandemic has led to great efforts to achieve effective vaccines with different approaches around the world, and different vaccine platforms have been developed against SARSCoV-2. Meanwhile, these technologies are still being investigated to obtain more data on the efficacy of combined vaccine platforms. The purpose of this study is to investigate the power of neutralizing antibodies of vaccinated people against COVID-19 in different vaccination regimens in Iran. We investigated Sinopharm/Sinopharm, Sinopharm/PastoCovac or Plus, AstraZeneca/AstraZeneca and AstraZeneca/ PastoCovac Plus recipients. The sera samples were collected from vaccinated individuals 3 weeks after the booster shots. cVNT test was done on the samples after sera dilution. The results showed that all the vaccine regimens induced neutralizing antibodies. Nevertheless, the combinational vaccine regimens in Sinopharm primed individuals showed greater neutralizing potency comparing to the homologous group. Moreover, PastoCovac Plus showed similar ability to AstraZeneca vaccine regarding neutralizing Wuhan and BA.5 variants.

Data on the safety of COVID-19 vaccines in obese or overweight subjects are limited and have been conducted in several studies with a small sample size worldwide. The aim of this study was to investigate and compare the incidence of adverse events after the first and second doses of Sinopharm and COVID-19 booster in overweight and obese subjects compared to normal weight subjects.

261 subjects who had received three doses of COVID-19 vaccine (two doses of Sinopharm + Sinopharm or PastoCovac or PastoCovac Plus booster) were enrolled in the study. Subjects' demographic characteristics and vaccine adverse events were recorded in a questionnaire during a telephone interview on days 7 and 21 after each dose of COVID-19 vaccine. Subsequently, the frequency of adverse events was compared between the 3 study groups.

Of the 261 participants, 59 were obese (BMI ≥ 30), 96 were overweight (BMI = 25-29.9), and 106 were normal weight (BMI = 24.9-18). The overall frequency of adverse events after all three doses of the COVID-19 vaccine was higher in obese subjects than in overweight or normalweight subjects. Pain at the injection site was the most common adverse event reported within seven days of booster vaccination in all groups. No adverse events occurred after receiving the PastoCovac booster in obese/overweight subjects, and the incidence of adverse events after PastoCovac plus booster and Sinopharm booster administration was similar. Overall, no serious vaccine-related adverse events were observed in the three groups.

The results of this study indicate that the inactivated and protein-based COVID -19 vaccines are safe and did not cause serious adverse events in obese or overweight individuals. In addition, the PasteCovac booster is more suitable for these people because it has no adverse effects. Therefore, further studies with a larger sample size are needed to identify a more effective booster with fewer adverse events in obese subjects

After the outbreak of SARS-CoV-2, another crisis has come to attention with the progression or persistence of symptoms of COIVD-19, known as long-COVID, which is very important due to the increasing number of reports of late-detected symptoms and their potential impact on the quality of life. In this study, long-term disorders were investigated in people who received three doses of the vaccines in order to distinguish between the side effects caused by COVID or the vaccine and the factors affecting it. Vaccinated people of four different vaccination regimens who received two doses of Sinopharm or AstraZeneca vaccines and got a booster dose of PastoCovac/Plus were followed from the first vaccine dose to 6 months after the booster shot. All adverse events were recorded through an in-depth interview using a researcher-made questionnaire, as well as COIVD-19 history and other demographics. Out of a total of 329 follow-up subjects, 30 cases (9.1%) were identified with long-term complications during the follow-up, who had at least one recorded history of COIVD-19 disease. The average age of these people was 40.5±9.3 and the average BMI was 27.23±4.6. The most common underlying diseases in this group were thyroid disorders (20%), hyper lipedema (10%) and hypertension (6%). The examination of registered complications showed that menstrual problems in women (30%), hair loss (20%), joint disorders (20%), headache (13%) and skin manifestations (10%) were the most common complications, respectively, and the identified symptoms were mainly stable until the end of the study with an average duration of 154 days. In 19 of these people, the vaccine was diagnosed as the main cause of the complication though there was no significant difference between the vaccine regimens. In the other 11 people, infection with SARS-CoV-2 was considered as the main trigger of the complication, although the role of the vaccine as a trigger for the exacerbation of complications cannot be neglected. In the current timeframe in which the vast majority of the world's population have got vaccinated against COIVD-19, it is difficult to identify late-onset disorders as side effects of vaccines or prolonged manifestations of COIVD-19. Therefore, some complications, though late, may be a possible consequence of SARS-CoV-2 infection or vaccination. This study has the advantage of long-term follow-up, which provides different forms of late events compared to the date of infection and vaccination of COIVD-19. The rate of late-onset disorders in the present study also highlights the importance of long-term follow-up studies in populations worldwide.

The present study aims to provide an insight to the comprehensive efforts of Pasteur Institute of Iran (PII) regarding COVID-19 management, research, achievements, and vaccine production, though there are many challenges. The relevant literature review was investigated through national and international database and also reports from the related research departments. Six strategies were taken by PII to manage the pandemic of COVID-19. While this pandemic has been hopefully controlled, SARS-CoV-2 could still be a potential threat. Therefore, COVID-19 data management and updated studies, as well as long-term safety and efficacy of the SARS-CoV-2 vaccines are still on the agenda.

Dendritic cells (DCs) play crucial roles in cellular immunity as the most powerful antigen presenting cells. They have been widely used for antigen delivery in vivo and in vitro. There are different ways to generate DCs and also gene transduction. In this study we introduce some optimization in order to produce high amount of well differentiated murine DCs for potential immunotherapy and vaccine development applications.

Murine bone marrow cells were isolated from male BALB/c mice and the cells were cultured with complete RPMI in presence of the same ratio of IL-4 and GM-CSF. Some changes were made in the medium and the lysis buffer applications to increase the differentiation rate of the cells. Lentiviral virions were applied to transfer the genes of interest to DCs with no pre-maturation steps. CD11c, MHC-II, CD80 and CD86 were assessed by flow cytometry.

The optimized steps led to significant increase in number of the isolated cells. IL-4 usage in a similar dose to GM-CSF led to macrophage formation inhibition. Lentiviral virions resulted in successful gene delivery along with well-maturated DCs.

The introduced optimized steps could be followed in different DC applications by using lentiviral virions to transduce DCs, independent of the pre-maturation steps.

Despite considerable efforts to control AIDS pandemic, it is still one of the significant infectious concerns worldwide. The advance in medical research has led to the development of highly active antiretroviral therapy with a considerable effect to suppress the disease. However, an effective vaccine capable of eradication the HIV pandemic is not available yet. Failure to develop a prophylactic vaccine diverted the efforts to clinical trials of therapeutic vaccines.

Here, we review different approaches to dendritic cell-based HIV therapeutic vaccines. We have summarized the dendritic cell-based trials as HIV therapeutic vaccination, registered in the United States clinical trial database. Results and

The strategies applied in the clinical trials were mostly of low success rates; however, by using dendritic cell therapy, they could trigger the host immune response against HIV-1 infections.